StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Rating) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.
Cumberland Pharmaceuticals Trading Down 1.9 %
Shares of CPIX stock opened at $2.61 on Tuesday. Cumberland Pharmaceuticals has a 1 year low of $1.89 and a 1 year high of $3.81. The firm has a fifty day moving average price of $2.34 and a 200-day moving average price of $2.36. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.94 and a quick ratio of 1.52. The company has a market cap of $38.27 million, a price-to-earnings ratio of -5.55 and a beta of 0.25.
Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Rating) last issued its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $0.09 earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 16.93% and a negative return on equity of 1.86%. The firm had revenue of $11.41 million during the quarter.
Institutional Inflows and Outflows
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals, Inc is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.
See Also
- Get a free copy of the StockNews.com research report on Cumberland Pharmaceuticals (CPIX)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.